# Pathware

> Analysis by Optimly for Optimly AI Visibility, in the Optimly AI Brand Index. Last analyzed September 25, 2026.

> Pathware provides real-time biopsy quality assessment with its Bioptic™ system to eliminate diagnostic delays and inadequate biopsies, reducing patient stress, repeat procedures, and healthcare costs for hospitals and insurance.

- Business Profile: https://optimly.ai/brand/pathware
- Publisher: Optimly (https://optimly.ai)
- Dataset: Optimly AI Brand Index (https://optimly.ai/brand)
- Official website: https://pathware.com/
- Logo: https://logo.clearbit.com/pathware.com
- Slug: pathware
- Brand Authority Index tier: Emerging
- Category: Clinical Diagnostic Systems
- Last Analyzed: September 25, 2026

## Buyer Intent Signals
Problems: Inadequate biopsies for diagnosis | Delays in biopsy diagnosis | Patient readmissions and re-biopsies | Intermediary patient stress due to diagnostic waits | Low billing potential for pathologists during on-site evaluations | High aggregate costs of repeat biopsy procedures and unnecessary surgeries | Unnecessary surgeries (e.g., thyroidectomies) following indeterminate biopsies | Financial losses for insurance due to unwarranted medical procedures
Solutions: Achieve real-time biopsy quality assessment | Ensure biopsy adequacy for diagnosis | Reduce the need for repeat biopsy procedures | Decrease patient stress related to diagnostic delays | Optimize pathologist efficiency during on-site evaluations | Lower healthcare costs associated with biopsies and surgeries | Prevent unnecessary surgeries through accurate, timely diagnosis
Comparisons: Biopsy adequacy rates | Diagnostic turnaround time for biopsies | Cost savings in biopsy procedures and related surgeries | Efficiency of on-site pathology assessment | Reduction in patient re-biopsies and readmissions | Accuracy of real-time diagnostic tools | Impact on insurance claims for medical procedures